Starpharma Holdings Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPHRY research report →
Price Chart
About the company
Starpharma Holdings Limited is an Australian biopharmaceutical company dedicated to advancing and marketing its proprietary dendrimer technology across global pharmaceutical, life-science, and other sectors. Among its current offerings are VivaGel, a non-antibiotic treatment designed for the management and prevention of bacterial vaginosis, alongside the antiviral VivaGel condom and VIRALEZE antiviral nasal spray. Furthermore, the company's extensive pipeline heavily features its DEP dendrimer drug delivery system, which includes several oncology candidates such as DEP docetaxel, DEP cabazitaxel, and DEP irinotecan, all currently undergoing Phase II clinical trials for various cancers.
- CEO
- Cheryl Maley
- IPO
- 2007
- Employees
- 50
- HQ
- Abbotsford, VIC, AU
Get TickerSpark's AI analysis on SPHRY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $242.03M
- P/E
- -48.83
- Fwd P/E
- 122.04
- PEG
- 0.36
- P/S
- 29.17
- P/B
- 26.19
- EV/EBITDA
- -18.62
- Div Yield
- 0.00%
- Gross Margin
- 86.26%
- Op Margin
- -159.60%
- Net Margin
- -61.95%
- ROE
- -42.35%
- ROIC
- -52.98%
Latest fiscal year · YoY change
- Revenue
- $11.79M+101.5%
- Gross Profit
- $10.17M+372.6%
- Op Income
- $-18,811,755
- Net Income
- $-7,301,879+26.9%
- EPS
- $-0.17+27.6%
- OCF Growth
- +52.5%
- FCF Growth
- +48.6%
- 52W High
- $5.98
- 52W Low
- $1.75
- 50D MA
- $5.29
- 200D MA
- $4.23
- Beta
- 0.77
- RSI (14)
- 56
- Avg Volume
- 828
No earnings-call transcripts are available for SPHRY yet.
- Free Float
- 69.9%
- Shares Outstanding
- 42.09M
- Float Shares
- 29.40M
Our SPHRY coverage
Recent articles, reports, and earnings notes.
No research on SPHRY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPHRY report →Starpharma (OTCMKTS:SPHRY) Stock Price Down 13.7% – Time to Sell?
defenseworld.net · Oct 4
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
prnewswire.com · Sep 15
Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma
seekingalpha.com · Aug 26
Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack
seekingalpha.com · Jun 21
Starpharma Up With News, Down With None; Timing Entry Makes Sense
seekingalpha.com · Feb 25
Starpharma signs DEP® ADC Research Agreement with MSD
prnewswire.com · Feb 11
Starpharma Viraleze: COVID-19 Nasal Spray Development
seekingalpha.com · Nov 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.